TriLink BioTechnologies Launches CleanAmp™ 7-deaza-dGTP for GC-rich Target Amplification
Complete the form below to unlock access to ALL audio articles.
When DNA targets high in GC-content are amplified, PCR product formation can often be compromised by inadequate strand separation and the propensity for complex secondary structure formation. The use of standard 7-deaza-dGTP is a notable method for overcoming this problem. TriLink has developed CleanAmp™ 7-deaza-dGTP, an elegant fusion of the secondary structure reducing nucleotide analog 7-deaza-dGTP and TriLink's CleanAmp™ dNTP Hot Start technology. CleanAmp™ 7-deaza-dGTP is available individually for amplification of routine GC-rich targets or as the CleanAmp™ 7-deaza-dGTP Mix which is recommended for more challenging targets with higher GC-content.
“Genetic disease diagnosis commonly involves the detection of GC-rich sequence elements, which have remained a stumbling block in the advancement of personalized medicine. CleanAmp™ 7-deaza-dGTP is our contribution to advancing this science. We hope it will become an invaluable tool,” stated CEO, Richard Hogrefe.
“The amplification of bacteria with high GC-content, such as the pathogenic mycobacterium, is essential for the diagnosis of many deadly diseases such as tuberculosis and leprosy. CleanAmp™ 7-deaza-dGTP shows promise for the diagnosis of these diseases and the possibility for earlier treatment,” stated Scientific Investigator, Natasha Paul.
